We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Guideline Eliminates Common Test for Diagnosing Heart Attacks

By LabMedica International staff writers
Posted on 30 Aug 2017
Heart disease remains the leading cause of death in men and women in the USA, and each year 735,000 Americans have heart attacks that damage the heart muscle, and of those, an estimated 120,000 die.

About one in five heart attacks are "silent," yielding no symptoms, but symptoms such as chest tightness or pain, dizziness, nausea and fatigue are good reasons to seek immediate evaluation. More...
Among the diagnostic tools to detect heart attacks are blood tests that measure levels of various proteins released into the bloodstream when heart cells are injured. Two of these are cardiac troponin and creatine kinase-myocardial band (CK-MB).

Scientists at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) and the Mayo Clinic (Rochester, MN, USA) have compiled peer-reviewed evidence and crafted a guideline designed to help physicians and medical centers stop the use of a widely ordered blood test that adds no value in evaluating patients with suspected heart attack.

The clinical and financial implications of institutions continuing CK-MB testing are significant, say the authors, who estimate that all blood tests for diagnosing heart attacks add USD 416 million each year to the cost of care. The team also cites studies showing that in addition to its diagnostic value, troponin testing is a more definitive predictor of in-hospital mortality and severity of disease. Professional guidelines concluded that CK-MB provides no additional diagnostic value for diagnosing heart attacks. It was found that 77% of nearly 2,000 laboratories in the U.S. still use CK-MB as a cardiac damage biomarker.

Jeffrey Trost, MD, an assistant professor of medicine and the corresponding author of the study, said, “This article is the first in a series of collaborative multi-institutional publications designed to bridge knowledge to high value practice. We present multiple quality improvement initiatives that safely eliminated CK-MB to give providers reassurance about trusting troponin levels when managing patients with suspected acute coronary syndrome.” The study was published on August 14, 2017, in the journal JAMA Internal Medicine.

Related Links:
Johns Hopkins University School of Medicine
Mayo Clinic


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.